FDA Extends EpiPen Expiration Dates to Tackle Shortage

Share this content:
FDA Extends EpiPen Expiration Dates to Tackle Shortage
FDA Extends EpiPen Expiration Dates to Tackle Shortage

TUESDAY, Aug. 21, 2018 (HealthDay News) -- The expiration dates of certain batches of EpiPens have been extended by the U.S. Food and Drug Administration in an effort to reduce shortages of the life-saving devices.

The FDA said that it has extended by four months the expiration dates of specific lots of 0.3 milligram EpiPens that are expired or close to expiring. The extension beyond the approved 20-month shelf life is based on data provided by EpiPen maker Mylan and reviewed by the FDA. The devices with the extended expiration dates have already been distributed to patients and should have been, and continue to be, stored as labeled, the FDA said.

"We're hopeful this action will ensure patients have access to this important medication and provide additional peace-of-mind to parents as the agency works with the manufacturer to increase supply," Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research, said in an agency news release.

EpiPens are still available in the United States, but are in limited supply in certain areas due to factors such as supply disruptions and manufacturer issues, according to the FDA. It said it's working closely with Mylan on EpiPen production and supply, and also has contacted other manufacturers of epinephrine auto-injectors about their supply.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »